psychodynamic treatment has also been described for patients with higher level personality pathology (Caligor, Clarkin, & Kernberg, 2007). @U%&(*0&#.! TFP for patients with borderline personality disorder has been empirically examined and supported in two randomized clinical trials, one in New York City (Clarkin, Levy, Lenzenweger, & Kernberg, 2007), and one in Europe (Doering, Hörz, Rentrop, Fischer-Kern, Schuster, Benecke, Buchheim, Martius, & Buchheim, 2010). In addition to symptom reduction, TFP resulted in an increase in narrative coherence and reflective functioning (Levy, Meehan, Kelly, Reynoso, Weber, Clarkin, & Kernberg, 2006), and improvement in personality organization (Doering, Hörz, Rentrop, Fischer- Kern, Schuster, Benecke, Buchheim, Martius, & Buchheim, 2010). We have isolated predictors of change and rates of change in the treatment of BPD patients (Lenzenweger, Clarkin, Levy, Yeomans, & Kernberg, 2012). 7&(2%&/.*)&2! Our current work builds on these previous findings. We are in the process of using pre-treatment genetic markers combined with neurocognitive functioning (fMRI) to predict response to TFP over a treatment episode of 18 months. A major goal of the extended treatment is not only symptom reduction, but also significant improvement in work functioning and satisfaction in interpersonal relations. G$#.1/.!
Prof. John Clarkin Personality Institute…… E-mail: jclarkin@med.cornell.edu
4'20&&;443&&32D.2E&&F&&19.3;&&2;.1.40&&GHIJ&&F& CKD
Made with FlippingBook Ebook Creator